Boehringer Ingelheim and the Atlanta Humane Society mark the grand opening of a unique pet adoption center in Metro Atlanta

DULUTH, Ga. (Sept. 4, 2019) — The Atlanta Humane Society and Boehringer Ingelheim, one of the leading animal health companies in the world, celebrate the grand opening Wednesday of the Atlanta Humane Society’s new pet-adoption center in Duluth, Georgia.

The adoption center, funded with help from Boehringer Ingelheim, pairs prospective pet owners with dogs and cats in a unique environment. Instead of kennels and cages, puppies play in one room while kittens stretch out for a nap in another. The center’s location in a corner storefront contributes to the goal of more adoptions more quickly.

“Boehringer Ingelheim believes in a future where no animal suffers from a preventable disease, and a big part of that involves finding good homes for dogs and cats in need,” said Everett Hoekstra, president of Boehringer Ingelheim’s U.S. Animal Health business. “We are proud to invest in the communities where we live and in organizations that create a better world for animals.”

“The Atlanta Humane Society serves thousands of animals each year, and we’re thrilled to have this new adoption center in Duluth to serve even more,” said Cal Morgan, President and CEO of the Atlanta Humane Society. “We’re proud to have partners like Boehringer Ingelheim who care so deeply about animal welfare to join us in furthering our mission.”

The Atlanta Humane Society’s pet-adoption center has placed 332 pets for adoption since opening with little fanfare on May 1. The Atlanta Humane Society expects that number to grow after the grand opening, which begins at 5 p.m. on Wed. Sept. 4 at the adoption center at 2148 Duluth Highway in Duluth.

Duluth also is the hometown of the headquarters of Boehringer Ingelheim’s U.S. Animal Health business, which employs more than 3,000 people in the U.S. The company has three sites in Georgia – in Duluth, Athens and Gainesville. It has invested more than $120 million and created 225 jobs in Georgia in the last few years.

In addition to providing financial support for the adoption center, Boehringer Ingelheim has provided financial support for the Atlanta Humane Society’s mobile spay-and-neuter service, which helps dogs and cats from all over metro Atlanta.

Boehringer Ingelheim has developed and manufactures some of the most trusted brands among veterinarians and animal lovers, including parasite-control products and vaccines that prevent disease and therapeutic products designed to effectively manage infections and chronic diseases.

About Atlanta Humane Society

The Atlanta Humane Society is the oldest private charitable organization in Atlanta, founded in 1873. Each year, more than 30,000 animals are served by the Atlanta Humane Society through programs and services such as spay/neuter, adoption, and veterinary care. It is the mission of the Atlanta Humane Society to prevent neglect, abuse, cruelty and exploitation of animals and to assure that their interests and well-being are fully, effectively and humanely protected by an aware and caring society. For more, visit atlantahumane.org. 

About Boehringer Ingelheim’s Animal Health business

Boehringer Ingelheim is the second largest animal health business in the world, with net sales of almost $4.7 billion (3.9 billion euros) worldwide in 2018, about 10,000 employees and a presence in more than 150 markets. The company has pioneered advancements in vaccines, parasite-control products and therapeutics that limit pain and slow disease, and aims to create the future of animal wellbeing for pets, horses and livestock by focusing on prevention.

Boehringer Ingelheim’s Animal Health Business has a significant presence in the United States, with more than 3,000 employees in places that include Georgia, Missouri, Iowa, Minnesota, New Jersey and Puerto Rico. To learn more, visit www.boehringer-ingelheim.us, www.facebook.com/BoehringerAHUS or www.twitter.com/Boehringer_AH.

About Boehringer Ingelheim

Improving the health of humans and animals is the goal of the research-driven pharmaceutical company Boehringer Ingelheim. The focus in doing so is on diseases for which no satisfactory treatment option exists to date. The company therefore concentrates on developing innovative therapies that can extend patients’ lives. In animal health, Boehringer Ingelheim stands for advanced prevention.

Family-owned since it was established in 1885, Boehringer Ingelheim is one of the pharmaceutical industry’s top 20 companies. Some 50,000 employees create value through innovation daily for the three business areas: human pharmaceuticals, animal health and biopharmaceuticals. In 2018, Boehringer Ingelheim achieved net sales of around $20.7 billion (17.5 billion euros). R&D expenditure of about $3.8 billion (3.2 billion euros), corresponded to 18.1 per cent of net sales.

As a family-owned company, Boehringer Ingelheim plans in generations and focuses on long-term success. The company therefore aims at organic growth from its own resources with simultaneous openness to partnerships and strategic alliances in research. In everything it does, Boehringer Ingelheim naturally adopts responsibility towards mankind and the environment.

Atlanta Humane Society Media Contact:
Christina Hill
Director of Marketing and Communications
248-786-7821
chill@atlantahumane.org